Charles Ruetsch, PhD

Descriptive Patterns Emerging From Initial Antidepressant Treatment Episodes in Patients with Treatment-Resistant Depression

Background: TRD leads to excess healthcare costs and burden of illness. Early patterns of antidepressant use may signify patients at high-risk for TRD. Methods: Eligible patients with ma...

John Verbanac , PhD;

Wing Chow , PharmD, MPH;

Jacqueline Pesa , PhD, MPH;

Charles Ruetsch , PhD;

Joshua Liberman , PhD;

Tigwa Davis , PhD;

Sara Heverly-Fitt , PhD;

11/22/2019

A Comparison of Barriers and Drivers Between Prescribing and Non-Prescribing Psychiatric Care Providers Regarding Use of Digital Medication Adherence Platforms

Background: Tracking medication adherence through an ingestible event monitoring (IEM) sensor could benefit seriously mentally ill patients (SMI). Psychiatric providers may be reluctant t...

Jennifer Clerie , BS ;

Charles Ruetsch , PhD;

Heidi Waters , PhD, MBA;

Tigwa Davis , PhD;

Dawn Velligan , PhD;

Delbert Robinson , MD;

Chris Jaeger , MD, MBA;

William Carpenter , MD;

Joshua Liberman , PhD;

Felicia Forma , BSc;

11/22/2019

Barriers and Drivers of Adopting a Digital Medication Adherence Technology: Understanding the Factor Analysis Results

Background: A new digital medicine technology combining an ingestible event monitoring (IEM) sensor with an oral antipsychotic to track ingestion and adherence may be beneficial. However,...

William Carpenter , MD;

Joshua Liberman , PhD;

Felicia Forma , BSc;

Charles Ruetsch , PhD;

Jennifer Clerie , BS ;

Tigwa Davis , PhD;

Heidi Waters , PhD, MBA;

Dawn Velligan , PhD;

Delbert Robinson , MD;

Chris Jaeger , MD, MBA;

11/22/2019

Early Assessment of Ustekinumab for Crohn’s Disease: A Chart Review

BACKGROUND: Ustekinumab was approved by the FDA in September 2016 for the treatment of patients with moderate-to-severe Crohn’s Disease (CD). Little is published about either the health a...

Antuane Allen ;

Jennifer Clerie , BS ;

Charles Ruetsch , PhD;

Tigwa Davis , PhD;

Erik Muser ;

James Izanec ;

Camilo Obando ;

11/20/2018

Relationship Between Patient Characteristics, Patterns of Treatment, and Medication Adherence Among Individuals with Major Depressive Disorder

Abstract: Background: Major depressive disorder (MDD) is associated with elevated health care and societal cost, increased morbidity and mortality, and diminished quality of life. First l...

Charles Ruetsch , PhD;

01/19/2023

Antidepressant and Psychotherapy Treatment among Patients With Major Depressive Disorder and an Elevated PHQ-9 Score

Background The PHQ-9 measures depression symptom severity and is recommended for use in clinical practice among patients with major depressive disorder (MDD). Objective To describe treat...

Charles Ruetsch , PhD;

Joshua Liberman , PhD;

Felicia Forma , BSc;

Pinyao Rui , PhD;

Alberto Batista , PharmD;

10/08/2020

The Cost of Improving Treatment Choices: Cost and Benefit of a Digital Medicine System that Collects and Reports Objective Medication Adherence

Background: Medication adherence is critical for relapse prevention among SMI patients. In the absence of objectively collected adherence data (OCAD), managing medications is difficult. A...

Felicia Forma , BSc;

Christopher P. Young , MD, PhD;

Charles Ruetsch , PhD;

Heidi Waters , PhD, MBA;

11/22/2019

Predicting Incident Treatment-Resistant Depression: A Model Designed for Health Care Systems

Background: Treatment resistant depression (TRD) is burdensome to health systems. Earlier identification of at-risk patients may reduce clinical inertia and improve outcomes.

Jacqueline Pesa , PhD, MPH;

Charles Ruetsch , PhD;

Joshua Liberman , PhD;

Tigwa Davis , PhD;

Sara Heverly-Fitt , PhD;

John Verbanac , PhD;

Wing Chow , PharmD, MPH;

11/22/2019